12 Health Care Stocks Moving In Monday’s Pre-Market Session
Gainers Scinai Immunotherapeutics (NASDAQ:SCNI) stock moved upwards by 77.4% to $6.19 during Monday’s pre-market session. The company’s market…
Why Skye Bioscience Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday’s Mid-Day Session
Shares of Skye Bioscience, Inc. (NASDAQ:SKYE) fell sharply during Monday’s session after the company announced its SBI-100 Ophthalmic…
12 Health Care Stocks Moving In Monday’s Intraday Session
Gainers Seres Therapeutics (NASDAQ:MCRB) stock moved upwards by 34.0% to $0.82 during Monday’s regular session. The company’s market…
Why Tharimmune (THAR) Shares Are Getting Hammered
Tharimmune shares are trading lower by 30% during Monday's session. The company late Friday announced it had entered into an "at the market" offering agreement.
Why Tharimmune (THAR) Shares Are Moving
Tharimmune shares are trading lower by 16.4% during Wednesday's session. The company announced a 1-for-15 reverse stock split.
12 Health Care Stocks Moving In Wednesday’s Pre-Market Session
Gainers Mustang Bio (NASDAQ:MBIO) stock increased by 51.6% to $0.47 during Wednesday’s pre-market session. The market value of…
Tharimmune’s Oral ‘Under The Cheek’ Candidate At Par With FDA-Approved Injectable With Potential For Chronic Liver Disease
Tharimmune achieves success in Phase 1 trial for TH104, a buccal film with nalmefene. Encouraging safety profile and potential for liver-related conditions.
Tharimmune Announces Results In Phase 1 Clinical Trial Of TH104, Compared Oral Transmucosal Delivery Of TH104 To Injectable Reference Approved Drug Completed
Positive safety/tolerability profile achieved with TH104 showing self-resolving, mild side effect profile aligned with previous studiesPhase 1 clinical trial compared oral transmucosal delivery of TH104 to injectable
12 Health Care Stocks Moving In Tuesday’s Pre-Market Session
Gainers Trxade Health (NASDAQ:MEDS) shares rose 207.2% to $14.1 during Tuesday’s pre-market session. The company’s market cap stands…
Tharimmune Announces Dosing Of First Patient In Phase 1 Clinical Trial Of TH104, Its Lead Candidate For Pruritus In Primary Biliary Cholangitis
Phase 1 clinical trial dosing of first patient complete; primary objective to assess safety/tolerability and absolute bioavailability of TH104Phase 1 study expected to be completed in 1Q24 with topline readout in